Asia
Gongda Xue has been found guilty in a Philadephia courtroom of stealing trade secrets from GlaxoSmithKline. This comes after his sister, Yu Xue, was also convicted for a similar crime.
Hutchmed failed to secure FDA approval for its proposed drug for pancreatic cancer. The company will have to go through another trial if they want U.S. approval.
Chimera’s research comes largely from its GOLD platform, a technology that reprograms RNA gene regulation circuits to alter chimeric antigen receptors (CAR) on T cells.
Global biopharmaceutical companies are pooling their respective resources against difficult-to-treat tumors, CNS diseases and idiopathic pulmonary fibrosis.
The Chinese government has halted the recommendation of Lianhua Qingwen used as a traditional Chinese treatment for mild cases of COVID-19.
The SEC added 12 China companies to their delisting watchlist this week. The companies will need to release evidence by May 3 to remain listed.
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
The funding will be used to push forward Aurion’s cell therapy program for corneal edema secondary to endothelial dysfunction.
The U.S. FDA greenlit China-based Triastek’s IND Application for its 3D printed drug product, T20, for cardiovascular and clotting disorders.
The data demonstrated that the drug, when given to the patients for more than seven days, offered a protection rate of 100%.
PRESS RELEASES